Diagnos (ADK) AI Stock Analysis

• Market Cap: C$22.41M
• Dividend Yield: N/A
• Average Volume (3M): 215.50K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.35
• Revenue Growth: -39.00%
• EPS Growth: -11.21%
• Country: CA
• Employees: 16
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.01
• Shares Outstanding: 101,862,976
• 10 Day Avg. Volume: 277,713
• 30 Day Avg. Volume: 215,497
• PEG Ratio: 1.01
• Price to Book (P/B): 93.95
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: C$0.00 ▼(-100.00%Downside)

The overall stock score for Diagnos is impacted significantly by its weak financial performance, which poses substantial risks. However, the positive corporate events provide some potential for future growth. Technical signals are mixed, and valuation concerns persist with ongoing losses and the absence of dividend returns.

Diagnos Business Overview & Revenue Model

Company Description

Diagnos (ADK) is a technology company specializing in healthcare solutions, primarily focusing on the development and deployment of artificial intelligence (AI) tools for the early detection and management of critical health conditions. The company's core product is its proprietary AI platform, which leverages advanced algorithms to analyze medical data and assist healthcare providers in diagnosing diseases more accurately and efficiently. Diagnos operates mainly within the healthcare and technology sectors, providing innovative solutions to enhance patient care outcomes.

How the Company Makes Money

Diagnos makes money through the licensing and subscription of its AI-powered diagnostic platform to healthcare institutions, clinics, and hospitals. The company charges fees for the usage of its software, which is typically integrated into the existing systems of healthcare providers to enhance diagnostic processes. Additionally, Diagnos may enter into partnerships or collaborations with medical device manufacturers and research institutions, generating revenue through joint ventures and shared projects. The company's earnings are also supported by potential government contracts and grants aimed at advancing healthcare technology and improving public health outcomes.

Diagnos Financial Statement Overview

Summary

Diagnos is experiencing severe financial distress with ongoing losses as evidenced by negative gross and net profit margins. The balance sheet shows high leverage and negative equity in some periods, and cash flows exhibit persistent negative operating cash flows, indicating significant financial and operational challenges.

Income Statement

Diagnos has faced significant challenges in its income statement, with consistent negative gross profit margins over the years, indicating that the cost of goods sold exceeds revenue. The net profit margins are deeply negative, reflecting ongoing losses. Revenue has shown volatility, with recent declines from previous periods, further exacerbating financial instability. The EBIT and EBITDA margins are also negative, suggesting operational inefficiencies.

Balance Sheet

The balance sheet reveals financial stress with high leverage as indicated by the debt-to-equity ratio. Stockholders' equity is negative in some years, pointing to a difficult financial position. The equity ratio is low, indicating a reliance on debt financing. These factors imply potential risks in financial stability and solvency.

Cash Flow

Cash flow analysis shows persistent negative operating cash flows, indicating challenges in generating cash from operations. Free cash flow remains negative, exacerbating liquidity concerns. Financing cash flows are positive, suggesting reliance on external financing to sustain operations. Overall, cash flow management appears strained with little improvement over time.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	103.80K	170.16K	438.83K	267.07K	331.52K
Gross Profit	-943.56K	35.80K	-418.30K	-347.53K	-473.45K
EBITDA	-3.56M	-2.45M	-2.10M	-2.45M	-1.93M
Net Income	-4.29M	-3.12M	-2.61M	-2.05M	-3.38M
Balance Sheet
Total Assets	3.64M	663.79K	1.54M	1.95M	2.43M
Cash, Cash Equivalents and Short-Term Investments	3.24M	219.01K	920.91K	1.36M	1.87M
Total Debt	3.07M	3.19M	1.19M	471.68K	337.55K
Total Liabilities	3.40M	3.72M	1.66M	818.19K	614.78K
Stockholders Equity	233.11K	-3.05M	-113.51K	1.13M	1.82M
Cash Flow
Free Cash Flow	-3.65M	-2.16M	-2.07M	-1.40M	-2.66M
Operating Cash Flow	-3.64M	-2.15M	-2.04M	-1.36M	-2.64M
Investing Cash Flow	-3.11M	-14.02K	503.52K	262.93K	-759.98K
Financing Cash Flow	6.62M	2.08M	1.60M	882.82K	3.83M

Diagnos Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.21
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ADK, the sentiment is Positive. The current price of 0.21 is above the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.21, and below the 200-day MA of 0.29, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.37 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ADK.

Diagnos Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AIML	55 Neutral	C$9.53M	―	-244.35%	―	-71.31%	-53.11%
ADK	51 Neutral	C$22.41M	―	366.78%	―	-39.00%	-11.21%
Sector *	46 Neutral	C$195.87M	-3.27	-23.14%	2.65%	20.75%	-0.36%
CHS	44 Neutral	C$9.69M	―	2.18%	―	-7.15%	97.22%
UDOC	34 Underperform	C$17.55M	―	-9999.00%	―	―	-50.06%
TRUE	34 Underperform	C$32.09M	―	-507.20%	―	-171.18%	46.80%

Diagnos Corporate Events

DIAGNOS Advances into U.S. Optometry Market with FDA Pre-Submission for CARA System

DIAGNOS Inc. has submitted a Pre-Submission to the U.S. FDA for its CARA System, marking a strategic move into the U.S. optometry market. The CARA System is an AI-driven platform that assists optometrists in detecting retinal and systemic diseases, enhancing efficiency and consistency in eye exams. With a robust dataset from 16 countries, the system aims to improve clinical decision-making and patient outcomes, potentially reshaping the optometry landscape.

DIAGNOS Strengthens US Advisory Board with Optometry Expert Dr. Barry Ginsberg

DIAGNOS has announced the addition of Dr. Barry A. Ginsberg, a veteran optometrist, to its Scientific Advisory Board in the United States. With over three decades of experience in various optometry settings, Dr. Ginsberg’s expertise in innovative product launches and ocular disease management is expected to enhance DIAGNOS’s market strategy and demonstrate the ROI of its AI-driven screening technology. This strategic move aligns with DIAGNOS’s recent expansion into the US market, marked by the opening of a new office in South Florida, and positions the company to tap into the growing demand for eye exams in the US.

Diagnos Strengthens US Market Position with New Advisory Board Member

Diagnos Inc., a leader in AI-driven healthcare solutions, has appointed Ed Weiner, a prominent figure in the optical industry, to its Advisory Board. This strategic move is expected to bolster Diagnos’s presence in the US optical market, leveraging Weiner’s extensive experience and connections. The company has also recently opened an office in South Florida to support its US operations, highlighting its commitment to expanding its market reach and addressing the growing demand for eye exams in the US.

Diagnos Inc. Strengthens US Market Strategy with New Advisory Board Member

Diagnos Inc. has announced the appointment of Dr. Tomas J. Philipson, a former White House Economic Adviser, to its Advisory Board, enhancing its strategic direction in the US market. This move is expected to bolster Diagnos’s market positioning in the healthcare sector, particularly in leveraging AI for eye health diagnostics, as the company expands its operations with a new office in South Florida to tap into the growing demand for eye exams.

DIAGNOS Engages Allele Capital for Strategic Advisory

DIAGNOS Inc. has engaged Allele Capital Partners to provide capital markets advisory and social media services. This partnership aims to refine DIAGNOS’s business strategy to optimize milestones and capital needs, ultimately enhancing shareholder value. The engagement is subject to TSX Venture Exchange acceptance and reflects DIAGNOS’s strategic efforts to strengthen its market position.

Diagnos Inc. Extends Convertible Debentures Maturity Date

Diagnos Inc. has announced an amendment to extend the maturity date of its $300,000 unsecured convertible debentures from May 18, 2025, to May 18, 2026. This decision, approved by the board of directors, aims to benefit the company and its shareholders, with all other provisions of the debentures remaining unchanged. The amendment is subject to TSX Venture Exchange acceptance and formal documentation execution, and it is exempt from certain valuation and minority approval requirements under MI 61-101 due to its limited impact on the company’s market capitalization.